Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial
Titel:
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial
Auteur:
Guigay, Joël Aupérin, Anne Fayette, Jérôme Saada-Bouzid, Esma Lafond, Cédrik Taberna, Miren Geoffrois, Lionnel Martin, Laurent Capitain, Olivier Cupissol, Didier Castanie, Hélène Vansteene, Damien Schafhausen, Philippe Johnson, Alison Even, Caroline Sire, Christian Duplomb, Sophie Evrard, Camille Delord, Jean-Pierre Laguerre, Brigitte Zanetta, Sylvie Chevassus-Clément, Cécile Fraslin, Aldéric Louat, Fanny Sinigaglia, Laura Keilholz, Ulrich Bourhis, Jean Mesia, Ricard